Eli Lilly and Company $LLY Shares Acquired by Cornerstone Wealth Group LLC

Cornerstone Wealth Group LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,661 shares of the company’s stock after buying an additional 128 shares during the period. Cornerstone Wealth Group LLC’s holdings in Eli Lilly and Company were worth $9,869,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. PNC Financial Services Group Inc. lifted its position in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Nuveen LLC acquired a new stake in Eli Lilly and Company in the first quarter worth approximately $4,613,912,000. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Cohen Investment Advisors LLC lifted its position in Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock worth $647,225,000 after purchasing an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after purchasing an additional 765,010 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $818.60 on Tuesday. The stock has a fifty day moving average of $743.43 and a 200-day moving average of $765.54. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The company has a market capitalization of $774.77 billion, a PE ratio of 53.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the business earned $3.92 EPS. The company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. Insiders own 0.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LLY. Berenberg Bank restated a “hold” rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Finally, Morgan Stanley cut their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $948.06.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.